1083 related articles for article (PubMed ID: 26170011)
21. Integrin-β4 identifies cancer stem cell-enriched populations of partially mesenchymal carcinoma cells.
Bierie B; Pierce SE; Kroeger C; Stover DG; Pattabiraman DR; Thiru P; Liu Donaher J; Reinhardt F; Chaffer CL; Keckesova Z; Weinberg RA
Proc Natl Acad Sci U S A; 2017 Mar; 114(12):E2337-E2346. PubMed ID: 28270621
[TBL] [Abstract][Full Text] [Related]
22. Dual regulation by microRNA-200b-3p and microRNA-200b-5p in the inhibition of epithelial-to-mesenchymal transition in triple-negative breast cancer.
Rhodes LV; Martin EC; Segar HC; Miller DF; Buechlein A; Rusch DB; Nephew KP; Burow ME; Collins-Burow BM
Oncotarget; 2015 Jun; 6(18):16638-52. PubMed ID: 26062653
[TBL] [Abstract][Full Text] [Related]
23. Clinicopathological significance of ZEB1 protein in patients with hepatocellular carcinoma.
Zhou YM; Cao L; Li B; Zhang RX; Sui CJ; Yin ZF; Yang JM
Ann Surg Oncol; 2012 May; 19(5):1700-6. PubMed ID: 21584833
[TBL] [Abstract][Full Text] [Related]
24. Pterostilbene inhibits triple-negative breast cancer metastasis via inducing microRNA-205 expression and negatively modulates epithelial-to-mesenchymal transition.
Su CM; Lee WH; Wu AT; Lin YK; Wang LS; Wu CH; Yeh CT
J Nutr Biochem; 2015 Jun; 26(6):675-85. PubMed ID: 25792283
[TBL] [Abstract][Full Text] [Related]
25. MiR-508-3p inhibits cell invasion and epithelial-mesenchymal transition by targeting ZEB1 in triple-negative breast cancer.
Guo SJ; Zeng HX; Huang P; Wang S; Xie CH; Li SJ
Eur Rev Med Pharmacol Sci; 2018 Oct; 22(19):6379-6385. PubMed ID: 30338806
[TBL] [Abstract][Full Text] [Related]
26. ΔNp63α attenuates tumor aggressiveness by suppressing miR-205/ZEB1-mediated epithelial-mesenchymal transition in cervical squamous cell carcinoma.
Zhao W; Wang H; Han X; Ma J; Zhou Y; Chen Z; Zhou H; Xu H; Sun Z; Kong B; Fang H
Tumour Biol; 2016 Aug; 37(8):10621-32. PubMed ID: 26864590
[TBL] [Abstract][Full Text] [Related]
27. Mesenchymal phenotype after chemotherapy is associated with chemoresistance and poor clinical outcome in esophageal cancer.
Hara J; Miyata H; Yamasaki M; Sugimura K; Takahashi T; Kurokawa Y; Nakajima K; Takiguchi S; Mori M; Doki Y
Oncol Rep; 2014 Feb; 31(2):589-96. PubMed ID: 24297447
[TBL] [Abstract][Full Text] [Related]
28. Overexpression of homeobox B-13 correlates with angiogenesis, aberrant expression of EMT markers, aggressive characteristics and poor prognosis in pancreatic carcinoma.
Zhai LL; Wu Y; Cai CY; Tang ZG
Int J Clin Exp Pathol; 2015; 8(6):6919-27. PubMed ID: 26261579
[TBL] [Abstract][Full Text] [Related]
29. Expression of cancer stem cell markers in basal and penta-negative breast carcinomas--a study of a series of triple-negative tumors.
Uchôa Dde M; Graudenz MS; Callegari-Jacques SM; Hartmann CR; Ferreira BP; Fitarelli-Kiehl M; Edelweiss MI
Pathol Res Pract; 2014 Jul; 210(7):432-9. PubMed ID: 24726267
[TBL] [Abstract][Full Text] [Related]
30. Correlation between epidermal growth factor receptor and tumor stem cell markers CD44/CD24 and their relationship with prognosis in breast invasive ductal carcinoma.
Zheng Z; Shao N; Weng H; Li W; Zhang J; Zhang L; Yang L; Ye S
Med Oncol; 2015 Jan; 32(1):275. PubMed ID: 25429827
[TBL] [Abstract][Full Text] [Related]
31. Tumor-associated macrophages correlate with phenomenon of epithelial-mesenchymal transition and contribute to poor prognosis in triple-negative breast cancer patients.
Zhang WJ; Wang XH; Gao ST; Chen C; Xu XY; Sun Q; Zhou ZH; Wu GZ; Yu Q; Xu G; Yao YZ; Guan WX
J Surg Res; 2018 Feb; 222():93-101. PubMed ID: 29273380
[TBL] [Abstract][Full Text] [Related]
32. Microenvironmental interactions and expression of molecular markers associated with epithelial-to-mesenchymal transition in colorectal carcinoma.
Lee SJ; Yang CS; Kim DD; Kang YN; Kwak SG; Park JB; Cho CH; Park KK
Int J Clin Exp Pathol; 2015; 8(11):14270-82. PubMed ID: 26823743
[TBL] [Abstract][Full Text] [Related]
33. Expression and prognostic significance of epithelial-mesenchymal transition-related markers and phenotype in serous ovarian cancer.
Song IH; Kim KR; Lim S; Kim SH; Sung CO
Pathol Res Pract; 2018 Oct; 214(10):1564-1571. PubMed ID: 30082157
[TBL] [Abstract][Full Text] [Related]
34. Epithelial-mesenchymal transition transcription factor ZEB1/ZEB2 co-expression predicts poor prognosis and maintains tumor-initiating properties in head and neck cancer.
Chu PY; Hu FW; Yu CC; Tsai LL; Yu CH; Wu BC; Chen YW; Huang PI; Lo WL
Oral Oncol; 2013 Jan; 49(1):34-41. PubMed ID: 22892238
[TBL] [Abstract][Full Text] [Related]
35. Pathological features of triple-negative breast cancers that showed progressive disease during neoadjuvant chemotherapy.
Tanabe Y; Tsuda H; Yoshida M; Yunokawa M; Yonemori K; Shimizu C; Yamamoto S; Kinoshita T; Fujiwara Y; Tamura K
Cancer Sci; 2017 Jul; 108(7):1520-1529. PubMed ID: 28474753
[TBL] [Abstract][Full Text] [Related]
36. Schlafen12 Reduces the Aggressiveness of Triple Negative Breast Cancer through Post-Transcriptional Regulation of ZEB1 That Drives Stem Cell Differentiation.
Al-Marsoummi S; Vomhof-DeKrey E; Basson MD
Cell Physiol Biochem; 2019; 53(6):999-1014. PubMed ID: 31838790
[TBL] [Abstract][Full Text] [Related]
37. The GRHL2/ZEB Feedback Loop-A Key Axis in the Regulation of EMT in Breast Cancer.
Mooney SM; Talebian V; Jolly MK; Jia D; Gromala M; Levine H; McConkey BJ
J Cell Biochem; 2017 Sep; 118(9):2559-2570. PubMed ID: 28266048
[TBL] [Abstract][Full Text] [Related]
38. Decreased expression of autophagy protein LC3 and stemness (CD44+/CD24-/low) indicate poor prognosis in triple-negative breast cancer.
Chang SJ; Ou-Yang F; Tu HP; Lin CH; Huang SH; Kostoro J; Hou MF; Chai CY; Kwan AL
Hum Pathol; 2016 Feb; 48():48-55. PubMed ID: 26772398
[TBL] [Abstract][Full Text] [Related]
39. ZEB1 promotes epithelial-mesenchymal transition in cervical cancer metastasis.
Ran J; Lin DL; Wu RF; Chen QH; Huang HP; Qiu NX; Quan S
Fertil Steril; 2015 Jun; 103(6):1606-14.e1-2. PubMed ID: 25963537
[TBL] [Abstract][Full Text] [Related]
40. Feasibility of Classification of Triple Negative Breast Cancer by Immunohistochemical Surrogate Markers.
Kim S; Moon BI; Lim W; Park S; Cho MS; Sung SH
Clin Breast Cancer; 2018 Oct; 18(5):e1123-e1132. PubMed ID: 29754847
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
